Mirum Pharmaceuticals, Inc.
MIRM
$96.55
$3.914.22%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -23.36M | -41.42M | -58.56M | -77.34M | -87.94M |
| Total Depreciation and Amortization | 24.24M | 24.23M | 24.22M | 24.02M | 23.63M |
| Total Amortization of Deferred Charges | 1.74M | 1.72M | 1.70M | 1.68M | 1.66M |
| Total Other Non-Cash Items | 72.92M | 67.56M | 62.41M | 57.44M | 50.39M |
| Change in Net Operating Assets | -19.72M | -7.39M | -20.77M | -12.65M | 22.59M |
| Cash from Operations | 55.83M | 44.69M | 9.00M | -6.85M | 10.33M |
| Capital Expenditure | -954.00K | -374.00K | -368.00K | -1.02M | -993.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -23.00M | -23.95M | -39.76M | -105.23M | -89.13M |
| Cash from Investing | -23.95M | -24.32M | -40.13M | -106.25M | -90.13M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 40.14M | 36.48M | 24.25M | 22.85M | 17.70M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 40.14M | 36.48M | 24.25M | 22.85M | 17.70M |
| Foreign Exchange rate Adjustments | 3.22M | 2.25M | 1.99M | -355.00K | -1.30M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 75.24M | 59.11M | -4.89M | -90.60M | -63.40M |